🔴 ACADIA Pharmaceuticals is trading 9.8% down in pre-market with no identified company-specific catalyst

ACADIA Pharmaceuticals is trading 9.8% lower at $22.95, with no fresh company-specific announcement identified to explain the pre-market decline.

• Shares fell from the September 23 close of $25.43.
• Investors remain focused on the upcoming September–October remlifanserin Phase 2 readout, a previously known milestone. Broader markets are weaker, while biotechnology is outperforming, leaving the unusually large decline unexplained.